These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 31807952)
1. The catecholaldehyde hypothesis: where MAO fits in. Goldstein DS J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952 [TBL] [Abstract][Full Text] [Related]
2. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know. Goldstein DS Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133 [TBL] [Abstract][Full Text] [Related]
3. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease. Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells. Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516 [TBL] [Abstract][Full Text] [Related]
5. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103 [TBL] [Abstract][Full Text] [Related]
6. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406 [TBL] [Abstract][Full Text] [Related]
7. The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases. Goldstein DS Semin Neurol; 2020 Oct; 40(5):502-514. PubMed ID: 32906170 [TBL] [Abstract][Full Text] [Related]
8. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664 [TBL] [Abstract][Full Text] [Related]
20. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]